Literature DB >> 21075825

Beneficial pulmonary effects of a metalloporphyrinic peroxynitrite decomposition catalyst in burn and smoke inhalation injury.

Matthias Lange1, Csaba Szabo, Perenlei Enkhbaatar, Rhykka Connelly, Eszter Horvath, Atsumori Hamahata, Robert A Cox, Aimalohi Esechie, Yoshimitsu Nakano, Lillian D Traber, David N Herndon, Daniel L Traber.   

Abstract

During acute lung injury, nitric oxide (NO) exerts cytotoxic effects by reacting with superoxide radicals, yielding the reactive nitrogen species peroxynitrite (ONOO(-)). ONOO(-) exerts cytotoxic effects, among others, by nitrating/nitrosating proteins and lipids, by activating the nuclear repair enzyme poly(ADP-ribose) polymerase and inducing VEGF. Here we tested the effect of the ONOO(-) decomposition catalyst INO-4885 on the development of lung injury in chronically instrumented sheep with combined burn and smoke inhalation injury. The animals were randomized to a sham-injured group (n = 7), an injured control group [48 breaths of cotton smoke, 3rd-degree burn of 40% total body surface area (n = 7)], or an injured group treated with INO-4885 (n = 6). All sheep were mechanically ventilated and fluid-resuscitated according to the Parkland formula. The injury-related increases in the abundance of 3-nitrotyrosine, a marker of protein nitration by ONOO(-), were prevented by INO-4885, providing evidence for the neutralization of ONOO(-) action by the compound. Burn and smoke injury induced a significant drop in arterial Po(2)-to-inspired O(2) fraction ratio and significant increases in pulmonary shunt fraction, lung lymph flow, lung wet-to-dry weight ratio, and ventilatory pressures; all these changes were significantly attenuated by INO-4885 treatment. In addition, the increases in IL-8, VEGF, and poly(ADP-ribose) in lung tissue were significantly attenuated by the ONOO(-) decomposition catalyst. In conclusion, the current study suggests that ONOO(-) plays a crucial role in the pathogenesis of pulmonary microvascular hyperpermeability and pulmonary dysfunction following burn and smoke inhalation injury in sheep. Administration of an ONOO(-) decomposition catalyst may represent a potential treatment option for this injury.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21075825      PMCID: PMC3043813          DOI: 10.1152/ajplung.00277.2010

Source DB:  PubMed          Journal:  Am J Physiol Lung Cell Mol Physiol        ISSN: 1040-0605            Impact factor:   5.464


  37 in total

1.  Peroxynitrite mediates cytokine-induced IL-8 gene expression and production by human leukocytes.

Authors:  C Zouki; L József; S Ouellet; Y Paquette; J G Filep
Journal:  J Leukoc Biol       Date:  2001-05       Impact factor: 4.962

2.  Vascular endothelial growth factor may contribute to increased vascular permeability in acute respiratory distress syndrome.

Authors:  D R Thickett; L Armstrong; S J Christie; A B Millar
Journal:  Am J Respir Crit Care Med       Date:  2001-11-01       Impact factor: 21.405

3.  Effect of poly(ADP ribose) synthetase inhibition on burn and smoke inhalation injury in sheep.

Authors:  Katsumi Shimoda; Kazunori Murakami; Perenlei Enkhbaatar; Lillian D Traber; Robert A Cox; Hal K Hawkins; Frank C Schmalstieg; Katalin Komjati; Jon G Mabley; Csaba Szabo; Andrew L Salzman; Daniel L Traber
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2003-03-07       Impact factor: 5.464

4.  Role of nitric oxide in vascular permeability after combined burns and smoke inhalation injury.

Authors:  K Soejima; L D Traber; F C Schmalstieg; H Hawkins; J M Jodoin; C Szabo; E Szabo; L Virag; A Salzman; D L Traber; L Varig
Journal:  Am J Respir Crit Care Med       Date:  2001-03       Impact factor: 21.405

5.  The inducible nitric oxide synthase inhibitor BBS-2 prevents acute lung injury in sheep after burn and smoke inhalation injury.

Authors:  Perenlei Enkhbaatar; Kazunori Murakami; Katsumi Shimoda; Akio Mizutani; Lillian Traber; Gary B Phillips; John F Parkinson; Robert Cox; Hal Hawkins; David Herndon; Daniel Traber
Journal:  Am J Respir Crit Care Med       Date:  2003-04-01       Impact factor: 21.405

Review 6.  The therapeutic potential of poly(ADP-ribose) polymerase inhibitors.

Authors:  László Virág; Csaba Szabó
Journal:  Pharmacol Rev       Date:  2002-09       Impact factor: 25.468

Review 7.  The biology of VEGF and its receptors.

Authors:  Napoleone Ferrara; Hans-Peter Gerber; Jennifer LeCouter
Journal:  Nat Med       Date:  2003-06       Impact factor: 53.440

Review 8.  The functional role of poly(ADP-ribose)polymerase 1 as novel coactivator of NF-kappaB in inflammatory disorders.

Authors:  P O Hassa; M O Hottiger
Journal:  Cell Mol Life Sci       Date:  2002-09       Impact factor: 9.261

Review 9.  Pathophysiological basis of smoke inhalation injury.

Authors:  Kazunori Murakami; Daniel L Traber
Journal:  News Physiol Sci       Date:  2003-06

10.  Changes in regional ventilation after autologous blood clot pulmonary embolism.

Authors:  Marcos F Vidal Melo; R Scott Harris; Dominick Layfield; Guido Musch; Jose G Venegas
Journal:  Anesthesiology       Date:  2002-09       Impact factor: 7.892

View more
  10 in total

1.  The clinically used PARP inhibitor olaparib improves organ function, suppresses inflammatory responses and accelerates wound healing in a murine model of third-degree burn injury.

Authors:  Akbar Ahmad; Gabor Olah; David N Herndon; Csaba Szabo
Journal:  Br J Pharmacol       Date:  2017-03-05       Impact factor: 8.739

2.  Lung [(18)F]fluorodeoxyglucose uptake and ventilation-perfusion mismatch in the early stage of experimental acute smoke inhalation.

Authors:  Guido Musch; Tilo Winkler; R Scott Harris; Marcos F Vidal Melo; Tyler J Wellman; Nicolas de Prost; Richard L Kradin; Jose G Venegas
Journal:  Anesthesiology       Date:  2014-03       Impact factor: 7.892

Review 3.  Therapeutic applications of PARP inhibitors: anticancer therapy and beyond.

Authors:  Nicola J Curtin; Csaba Szabo
Journal:  Mol Aspects Med       Date:  2013-01-29

Review 4.  Simple biological systems for assessing the activity of superoxide dismutase mimics.

Authors:  Artak Tovmasyan; Julio S Reboucas; Ludmil Benov
Journal:  Antioxid Redox Signal       Date:  2013-10-19       Impact factor: 8.401

Review 5.  SOD therapeutics: latest insights into their structure-activity relationships and impact on the cellular redox-based signaling pathways.

Authors:  Ines Batinic-Haberle; Artak Tovmasyan; Emily R H Roberts; Zeljko Vujaskovic; Kam W Leong; Ivan Spasojevic
Journal:  Antioxid Redox Signal       Date:  2013-10-01       Impact factor: 8.401

6.  Differential coordination demands in Fe versus Mn water-soluble cationic metalloporphyrins translate into remarkably different aqueous redox chemistry and biology.

Authors:  Artak Tovmasyan; Tin Weitner; Huaxin Sheng; MiaoMiao Lu; Zrinka Rajic; David S Warner; Ivan Spasojevic; Julio S Reboucas; Ludmil Benov; Ines Batinic-Haberle
Journal:  Inorg Chem       Date:  2013-05-06       Impact factor: 5.165

7.  Effects of simvastatin on iNOS and caspase‑3 levels and oxidative stress following smoke inhalation injury.

Authors:  Rong-Qiang Yang; Peng-Fei Guo; Zhao Ma; Cheng Chang; Qing-Nan Meng; Ya Gao; Imran Khan; Xiao-Bo Wang; Zheng-Jun Cui
Journal:  Mol Med Rep       Date:  2020-08-04       Impact factor: 2.952

Review 8.  Preclinical and clinical studies of smoke-inhalation-induced acute lung injury: update on both pathogenesis and innovative therapy.

Authors:  Bingxin Guo; Yichun Bai; Yana Ma; Cong Liu; Song Wang; Runzhen Zhao; Jiaxing Dong; Hong-Long Ji
Journal:  Ther Adv Respir Dis       Date:  2019 Jan-Dec       Impact factor: 4.031

Review 9.  Diagnosis and management of inhalation injury: an updated review.

Authors:  Patrick F Walker; Michelle F Buehner; Leslie A Wood; Nathan L Boyer; Ian R Driscoll; Jonathan B Lundy; Leopoldo C Cancio; Kevin K Chung
Journal:  Crit Care       Date:  2015-10-28       Impact factor: 9.097

Review 10.  Emerging therapies for smoke inhalation injury: a review.

Authors:  Alexandra Mercel; Nick D Tsihlis; Rob Maile; Melina R Kibbe
Journal:  J Transl Med       Date:  2020-03-30       Impact factor: 5.531

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.